Convergent Genomics Home
  • About Us
  • Our Products
  • Our Science
  • Clinical Expertise
  • Newsroom
  • Contact
  • About Us
  • Our Products
  • Our Science
  • Clinical Expertise
  • Newsroom
  • Contact

NEW STUDY SHOWS UROAMP CAN DETECT BLADDER CANCER NOT FOUND BY CYSTOSCOPY OR URINE CYTOLOGY

by admin | Aug 22, 2023 | Press releases

Noninvasive Genomic Urine Test Demonstrates High Accuracy in Predicting Recurrence Before Clinical Signs or Symptoms Emerge SOUTH SAN FRANCISCO, Calif., Aug. 22, 2023 /PRNewswire/ — UroAmp, the noninvasive genomic urine test developed by Convergent Genomics, can...

Genomic Urine Test Detects Bladder Cancer from DNA Up to 12 Years Before Clinical Signs and Symptoms Appear

by admin | Apr 27, 2023 | Press releases

Advances in Next-Generation DNA Sequencing and Machine Learning Enable Rapid Analysis of Genetic Mutations to Determine Cancer Risk CHICAGO – May 1, 2023 – A new genomic urine test can help doctors accurately predict bladder cancer as many as 12 years before clinical...

New Studies on Convergent Genomics’ Urine Test for Bladder Cancer to be Presented at 2023 American Urological Association (AUA) Annual Meeting

by admin | Apr 25, 2023 | Press releases

CHICAGO, April 25, 2023 /PRNewswire/ — Convergent Genomics announced UroAmp, the company’s genomic urine test that uses next-generation DNA sequencing and machine learning to detect and monitor for bladder cancer, will be the subject of two new studies...

Contact us
425 Eccles Ave, South San Francisco, CA 94080
info@convergentgenomics.com
415-839-0077




Privacy Policy

Financial Conflict of
Interest Policy

References

The UroAmp test has been developed, its performance characteristics determined, and validated by our CLIA-certified laboratory, which performs the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.